BIOQUAL Announces Changes to Board of Directors
BIOQUAL (BIOQ) announced changes to its Board of Directors. Charles Francisco, who served as a director since 1992, retired effective December 31, 2024, at age 85. His retirement was not related to any disagreements with Board policies or practices.
Amy Johnston joined the Board on December 31, 2024, maintaining the same number of directors. Johnston brings over 30 years of healthcare and biotech industry experience. Her notable achievements include leading commercial biotech teams, supporting a Hepatitis C compound launch that achieved $1B in first-year sales, and successfully increasing a utility company's revenue from $10 million to $25 million during the pandemic. She holds dual Bachelor's degrees in Government and English and a Master's in Secondary English Education from the College of William and Mary.
BIOQUAL (BIOQ) ha annunciato cambiamenti nel suo Consiglio di Amministrazione. Charles Francisco, che è stato direttore dal 1992, si è ritirato con effetto dal 31 dicembre 2024, all'età di 85 anni. Il suo ritiro non era legato a disaccordi con le politiche o le pratiche del Consiglio.
Amy Johnston è entrata a far parte del Consiglio il 31 dicembre 2024, mantenendo lo stesso numero di direttori. Johnston porta con sé oltre 30 anni di esperienza nel settore sanitario e biotecnologico. I suoi risultati notevoli includono la guida di team commerciali biotecnologici, il supporto per il lancio di un composto per l'Epatite C che ha raggiunto 1 miliardo di dollari in vendite nel primo anno e l'aumento con successo del fatturato di un'azienda di servizi da 10 milioni a 25 milioni di dollari durante la pandemia. Possiede una doppia laurea in Governo e Inglese e un Master in Educazione all'Inglese Secondario presso il College of William and Mary.
BIOQUAL (BIOQ) anunció cambios en su Junta Directiva. Charles Francisco, quien ha sido director desde 1992, se retiró a partir del 31 de diciembre de 2024, a la edad de 85 años. Su retiro no estuvo relacionado con ningún desacuerdo con las políticas o prácticas de la Junta.
Amy Johnston se unió a la Junta el 31 de diciembre de 2024, manteniendo el mismo número de directores. Johnston aporta más de 30 años de experiencia en la industria de la salud y biotecnología. Sus logros notables incluyen la dirección de equipos comerciales de biotecnología, el apoyo a un lanzamiento de un compuesto para la Hepatitis C que logró 1 mil millones de dólares en ventas en su primer año, y el aumento exitoso de los ingresos de una empresa de servicios de 10 millones a 25 millones de dólares durante la pandemia. Posee dobles títulos de licenciatura en Gobierno e Inglés y una Maestría en Educación en Inglés Secundario del College of William and Mary.
BIOQUAL (BIOQ)는 이사회의 변경 사항을 발표했습니다. 찰스 프란시스코는 1992년부터 이사로 재직하다가 2024년 12월 31일부로 85세에 은퇴했습니다. 그의 은퇴는 이사회 정책이나 관행과의 불일치와는 무관했습니다.
에이미 존스턴은 2024년 12월 31일에 이사회에 합류하여 이사 수를 유지합니다. 존스턴은 헬스케어 및 생명공학 산업에서 30년 이상의 경험을 가지고 있습니다. 그녀의 주요 성과에는 상업 생명공학 팀을 이끌고, 1년 차 매출 10억 달러를 기록한 간염 C 화합물 출시를 지원하며, 팬데믹 동안 유틸리티 회사의 매출을 1천만 달러에서 2천5백만 달러로 성공적으로 증가시킨 경험이 포함됩니다. 그녀는 윌리엄 앤 메리 대학교에서 정부학과 영어의 이중 학위를 받고, 중등 영어 교육 석사학위를 취득했습니다.
BIOQUAL (BIOQ) a annoncé des changements au sein de son Conseil d'Administration. Charles Francisco, qui a été directeur depuis 1992, a pris sa retraite à compter du 31 décembre 2024, à l'âge de 85 ans. Sa retraite n'était pas liée à des désaccords avec les politiques ou les pratiques du Conseil.
Amy Johnston a rejoint le Conseil le 31 décembre 2024, maintenant le même nombre de directeurs. Johnston a plus de 30 ans d'expérience dans le secteur de la santé et des biotechnologies. Ses réalisations notables incluent la direction d'équipes commerciales en biotechnologie, le soutien au lancement d'un composé pour l'hépatite C ayant généré 1 milliard de dollars de ventes la première année, et l'augmentation réussie des revenus d'une entreprise de services de 10 millions à 25 millions de dollars pendant la pandémie. Elle détient des diplômes de Bachelor en Gouvernement et en Anglais ainsi qu'un Master en Éducation en Anglais de Niveau Secondaire du College of William and Mary.
BIOQUAL (BIOQ) gab Änderungen im Vorstand bekannt. Charles Francisco, der seit 1992 im Vorstand war, trat zum 31. Dezember 2024 im Alter von 85 Jahren zurück. Sein Rücktritt war nicht auf Meinungsverschiedenheiten über die politischen oder praktischen Vorgehensweisen des Vorstands zurückzuführen.
Amy Johnston trat am 31. Dezember 2024 dem Vorstand bei und behielt die gleiche Anzahl von Direktoren bei. Johnston bringt über 30 Jahre Erfahrung in der Gesundheits- und Biotechnologiebranche mit. Zu ihren bemerkenswerten Leistungen gehören das Führen von kommerziellen Biotech-Teams, die Unterstützung eines Hepatitis-C-Produktlaunches, der im ersten Jahr 1 Milliarden Dollar Umsatz erzielte, sowie die erfolgreiche Steigerung des Umsatzes eines Versorgungsunternehmens von 10 Millionen auf 25 Millionen Dollar während der Pandemie. Sie hat Doppelabschlüsse in Regierungswissenschaft und Englisch sowie einen Masterabschluss in Sekundarbildung in Englisch vom College of William and Mary.
- New board member Amy Johnston brings 30+ years of healthcare and biotech industry experience
- Johnston's track record includes leading a $1B first-year sales achievement for a Hepatitis C compound
- Demonstrated business growth expertise, having increased revenue from $10M to $25M in previous role
- None.
BIOQUAL, Inc., announced today that Mr. Charles Francisco retired from his role as a BIOQUAL Board Member effective December 31, 2024. Mr. Francisco is 85 years old and has served as a director since 1992. His retirement is not connected to any disagreements with the Board’s policies or practices.
Additionally, on December 31, 2024 BIOQUAL welcomed Ms. Amy Johnston to the BIOQUAL Board of Directors. Ms. Johnston will replace Mr. Francisco on the Board, thus, the number of directors will not change. Ms. Johnston has been working with and managing companies in the healthcare and biotech industries for over thirty years. She holds a Bachelor of Arts in Government and English (dual degree) and a Master of Arts degree in Secondary English Education from the College of William and Mary in
- Led cross-functional teams to build commercial biotech teams and strategies while ensuring compliance with FDA regulations,
-
Provided critical support in pre-launch and post-launch efforts for a Hepatitis C compound, achieving
$1B - Collaborated with media and advertising agencies, managed market teams, Key Opinion Leaders, and patient advocacy groups to educate both the medical community and the patients,
-
By revising the strategy and operating model of a design/build employee-owned utility company, Amy and her business partner increased revenue from
$10 million $25 million
Forward Looking Information
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and one should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114814467/en/
Mark G. Lewis, Ph.D., CEO (240-404-7654)
Source: BIOQUAL, Inc.
FAQ
When did Charles Francisco retire from BIOQUAL's (BIOQ) Board of Directors?
Who replaced Charles Francisco on BIOQUAL's (BIOQ) Board of Directors?
What is Amy Johnston's educational background for her role on BIOQUAL's (BIOQ) Board?
What major commercial success did new BIOQUAL (BIOQ) board member Amy Johnston achieve in healthcare?
How long did Charles Francisco serve on BIOQUAL's (BIOQ) Board before retiring?
